Navigation Links
Talecris Biotherapeutics Announces First Quarter 2011 Results
Date:4/27/2011

uction progressed to the capital phase.  Inventory impairment provisions during the first quarter of 2011 decreased by $5.2 million to $7.1 million.  Unabsorbed TPR infrastructure and start-up costs during the first quarter of 2011 declined by $1.6 million to $0.4 million.  Production costs during the first quarter of 2011 increased $17.1 million driven by slower than planned reduction in Talecris' cost per liter of plasma, yield variability as well as inefficient plasma utilization.  Gross margin was 42.6% during the first quarter of 2011 compared to 42.9% for the 2010 first quarter.  

Operating expenses for the first quarter of 2011 were $79.2 million, which represented a decrease of $4.6 million or 5.5% versus $83.9 million incurred during the prior year period.  The decrease in operating expenses resulted from a decrease in SG&A expenses primarily driven by a $4.1 million reduction in share-based compensation and lower special recognition bonus expense of $1.2 million.  During the three months ended March 31, 2011, SG&A benefited from $1.3 million in favorable foreign exchange transactions compared to unfavorable foreign exchange transactions of $3.9 million the first quarter of 2010.  These decreases were partially offset by $2.9 million in higher sales and marketing expense in the first quarter of 2011 as the result of the sales force expansion.  In addition, the company incurred $3.4 million in merger- related expenses, including $2.3 million in retention expenses in SG&A related to the definitive merger agreement with Grifols.  R&D spending increased slightly in the first quarter of 2011, driven by increased activity in the phase II trial for Plasmin in the treatment of acute peripheral arterial occlusion (aPAO).  Operating income was $93.8 million during the first quarter of 2011, which represented a 17.7% increase over the $79.7 million reported during the first quarter of 2010.
'/>"/>

SOURCE Talecris Biotherapeutics Holdings Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
2. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
3. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
4. Siemens/Talecris Win Best Partnership in the Outsourcing Excellence Awards
5. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
6. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
7. Talecris Added to NASDAQ Biotechnology Index
8. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
9. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
10. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
11. Talecris Biotherapeutics Announces Premerger HSR Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pittcon is pleased to announce that ... Matsuda, Horiba Scientific, have organized a session on nanotechnology ... JASIS , Asia’s largest analytical and scientific instruments show, ... Japan. , The four speakers in this U.S. ... Molecules to Single Cells” will present their use of ...
(Date:8/29/2014)... MA (PRWEB) August 29, 2014 A ... in the biotech start-up dense realm of Boston-Cambridge, is ... and able investors. James Sherley, the Director of Boston’s ... increasing the local and national visibility of his company ... September 2013. , In addition to a social media ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and ... 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for ... owners and USDA-GIPSA inspection agencies that have a need to ... place in a matter of minutes with nothing but our ... feed and grain before accepting it, but they no longer ...
(Date:8/28/2014)... Aug. 28, 2014  Next month, executives from clinical trial ... industry events beginning with Patient-Centered Clinical Trials 2014 , ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits of ... of tactics – from media to mobile apps – can ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4BBK Worldwide Leads Sessions at Key September Events 2
... Conference on Lung Cancer in Seoul, Korea, ... Inc.,(AMEX: YMI , TSX: YM, AIM: YMBA), ... products for patients worldwide,today announced positive preliminary results ... part of a Phase I/II trial of nimotuzumab ...
... the Biotech,Industry, Bank of America Investment, and UBS Global Life Sciences ... ... Sept. 4 Trubion Pharmaceuticals,Inc. (Nasdaq: TRBN ) announced today ... will present an overview,of the company at three September investor conferences: ...
... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical ... cancer and,hepatitis C virus (HCV) infection, today announced that ... ended July 31, 2007 on September,10, 2007, and will ... at 11:30 a.m. EDT on the same day. ...
Cached Biology Technology:YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 2YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 3YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 4YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 5Trubion Pharmaceuticals to Present at Upcoming Investor Conferences 2Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results 2
(Date:8/28/2014)... , Aug. 28, 2014  Privacy Advocate and Senior ... Jennifer Lynch , joins the lineup of biometric and ... annual Biometrics UnPlugged Executive Summit in Tampa, ... Previously announced speakers include Steven Rahman, Director, Technology and ... Sector at Experian. The theme of this year,s event ...
(Date:8/28/2014)... the most commonly diagnosed learning disability in the ... occurs when the regions of the brain that ... use of non-invasive functional neuroimaging tools has helped ... However, most prior work has focused on only ... gap in our understanding of how multiple brain ...
(Date:8/28/2014)... Alaska totaled 515 million board feet in volume in ... than 10 percent compared to the first quarter of ... reported today. During this same period, West coast lumber ... feet. , The total value of these log exports ... in the same quarter, while the total value of ...
Breaking Biology News(10 mins):Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2Dyslexic readers have disrupted network connections in the brain 2West coast log exports up, lumber exports down in second quarter of 2014 2
... sense of touch, researchers have shown. A study, by Dr ... at the University of Surrey, has found that Bacillus mycoides ... forces and curvature in the medium on which it,s growing. ... as revealed in the journal PLOS ONE , could signal ...
... in German . ... More precise tests may allow allergy sufferers more freedom of food ... out by the Helmholtz Centre for Environmental Research (UFZ), the University ... examined patients with a Nile perch allergy. Being allergic to Nile ...
... - December 10, 2013 Researchers at the Icahn ... strain of influenza the virus that causes the flu ... even after it develops resistance to antiviral medications. The finding was ... Nature Communications . It is not uncommon for ...
Cached Biology News:The garden microbe with a sense of touch 2Each food fish can cause specific allergies 2Each food fish can cause specific allergies 3Mount Sinai researchers say new strain of bird flu packs a punch even after becoming drug-resistant 2